Board of Directors


Alan C. Nelson, PhD – Chairman of the Board

Dr. Nelson, is founder, chairman and CEO of VisionGate®. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.

Walter Robb, PhD – Board Director

Dr. Robb is currently a management consultant and president of Vantage Management, Inc. He serves on the board of Mechanical Technology, Inc., eight private, start-up companies and is a former Celgene board member. He previously served as senior vice president for General Electric’s Corporate Research and Development center, one of the world’s largest and most diversified industrial laboratories, and served on the company’s Corporate Executive Council. Additionally, he headed GE Medical Systems for 13 years.

Thomas J. Miller – Board Director

Thomas Miller is the current founder of GreyBird Ventures, an umbrella company for consulting, investment, and management opportunities. Prior to founding GreyBird Ventures, Mr. Miller served in numerous executive roles, most recently acting as CEO of the Customer Solutions Division at Siemens Healthcare where he was responsible for all downstream activities regarding healthcare, IT and new services for 26,000 employees in more 130 countries. Mr. Miller has been featured in Diagnostic Imaging magazine in its cover story on “The 20 Most Influential People in Diagnostic Radiology”.

James Burns, DLS – Board Director

Dr. Burns has executive experience in the pharmaceutical, biotechnology, medical device, and diagnostic fields ranges from CEO, C-suite executive, company founder, commercialization, finance, and general management. He has worked within businesses from early-stage companies to large multinational corporations, venture capital, and private equity. Most recently, Jim served as Chairman of the Board, Executive Chairman and as President & Chief Executive Officer of Assurex Health, Inc., acquired by Myriad Genetics in 2016. Jim is a Board Leadership Fellow of the U.S. National Association of Corporate Directors (NACD). He earned B.S. and M.S. degrees in Biological Sciences from the University of Illinois, an M.B.A. from DePaul University, and a D.L.S. from Georgetown University.

Michael Doherty – Board Director

Michael Doherty has 25 years of global pharmaceuticals industry experience including the most recent 14 years at Roche Pharmaceuticals and Genentech as Head of Regulatory Affairs overseeing the approvals of products in the field of oncology, immunology, hematology and bone disease. He is currently Head of Product Development at Foundation Medicine, where he leads a team dedicated to the introduction of clinical and data products in the field of cancer genomics based on Next-Generation Sequencing. Mr. Doherty serves as a Regulatory Strategy Advisory advisor to VisionGate, Inc., as a Strategic Advisor to Genentech Product Development and on the advisory board of IBM Watson Life Sciences.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2020 - VisionGate, Inc.